EPRX

Eupraxia Pharmaceuticals

3.06 USD
-0.03
0.97%
Updated Dec 24, 9:36 AM EST
1 day
-0.97%
5 days
-7.27%
1 month
-10.26%
3 months
12.09%
6 months
15.91%
Year to date
3.73%
1 year
3.73%
5 years
3.73%
10 years
3.73%
 

About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

Employees: 29

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3% more capital invested

Capital invested by funds: $4.43M [Q2] → $4.55M (+$113K) [Q3]

0.2% more ownership

Funds ownership: 4.85% [Q2] → 5.05% (+0.2%) [Q3]

0% more funds holding

Funds holding: 8 [Q2] → 8 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$9
194%
upside
Avg. target
$9
194%
upside
High target
$9
194%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Rodman & Renshaw
Brandon Folkes
54% 1-year accuracy
7 / 13 met price target
194%upside
$9
Buy
Initiated
14 Nov 2024

Financial journalist opinion

Neutral
PRNewsWire
1 month ago
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety In clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritis DiffuSphere™ has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancers VICTORIA, BC , Nov. 20, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery.
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
VICTORIA, BC , Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the American College of Rheumatology (the "ACR") Convergence 2024 Annual Meeting, being held in Washington, D.C. from November 14-19, 2024.
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence Registration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.com VICTORIA, BC , Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed".
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
VICTORIA, BC , Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
VICTORIA, BC , Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement"). The Company intends to use the net proceeds from the Private Placement towards the funding of clinical trials for EP104GI, initiating research programs for new candidates and general corporate and working capital purposes of the Company and its affiliates.
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Neutral
PRNewsWire
1 month ago
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
VICTORIA, BC , Oct. 28, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting two posters at the American College of Gastroenterology ("ACG") Annual Scientific Meeting 2024, being held in Philadelphia, PA, on October 25-30, 2024. The event is a premier gastrointestinal ("GI") clinical meeting and the ACG is a recognized leader in educating GI professionals and the general public about digestive disorders.
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Neutral
PRNewsWire
2 months ago
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet Rheumatology, Eupraxia's EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportionate concentrations in plasma.
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Neutral
PRNewsWire
2 months ago
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
VICTORIA, BC , Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the upcoming United European Gastroenterology ("UEG") Week 2024 to be held in Vienna, Austria, on October 12-15, 2024. The event is one of the foremost conferences for researchers globally to present their latest findings in the field of gastroenterology.
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Neutral
PRNewsWire
2 months ago
Eupraxia Pharmaceuticals Strengthens Senior Management Team
VICTORIA, BC , Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the recent appointments of Chief Scientific Officer Amanda Malone, as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development. "These appointments strengthen and round out our senior leadership team as we continue to advance the DiffuSphere™ technology, co-developed by Dr. Malone, into increasingly later-stage clinical settings," said Dr. James Helliwell, CEO of Eupraxia.
Eupraxia Pharmaceuticals Strengthens Senior Management Team
Charts implemented using Lightweight Charts™